Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine

Semin Cancer Biol. 2003 Dec;13(6):409-15. doi: 10.1016/j.semcancer.2003.09.004.

Abstract

The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

Publication types

  • Review

MeSH terms

  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use*
  • Clinical Trials as Topic
  • HLA Antigens / immunology
  • Humans
  • Immunotherapy, Active
  • Melanoma / immunology*
  • Melanoma / therapy*
  • Neoplasm Staging
  • Skin Neoplasms / immunology
  • Skin Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Cancer Vaccines
  • HLA Antigens
  • Melacine